LearnGlossaryMarketStocksSuperinvestorsSign in

TNGX

Tango Therapeutics, Inc.

Healthcare · $3.9B market cap

Verdict

We can't put a fair value on TNGX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-17.2% a year✗
Sales growth22.6% a year✓
Free cash flow growth—?
Return on invested capital-37.7%✗

Follow TNGX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases, 1 sale worth $604K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Crystal Adam

President, R&D · 2026-09-01

Sold

$604K

Other filings

Crystal Adam

President, R&D · 2026-09-01

Option exercise

$140K

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works